id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-P-0595-0007,FDA,FDA-2009-P-0595,"Attachment B - ""Meridia (Sibutramine) United States Food and Drug Administration Endocrinologic and Metabolic Drug Advisory Committee Meeting on September 15, 2010"" - [Abbott Laboratories, Inc. - Comment]",Supporting & Related Material,C-Comment (Supporting and Related Material),2011-01-28T05:00:00Z,2011,1,,,2011-01-28T21:21:32Z,,0,0,0900006480b61f7c
FDA-2009-P-0595-0006,FDA,FDA-2009-P-0595,"Attachment A - ""Advisory Committee Briefing Document for Meridia (Sibutramine HydrochloridemMonohydrate) Endocrinologic and Metabolic Drug Advisory Committee Meeting on September 15, 2010"" - [Abbott Laboratories, Inc. - Comment]",Supporting & Related Material,C-Comment (Supporting and Related Material),2011-01-28T05:00:00Z,2011,1,,,2011-01-28T21:20:58Z,,0,0,0900006480b61f7a
FDA-2009-P-0595-0005,FDA,FDA-2009-P-0595,FDA/CDER to Public Citizen's Health Research Group -  Petition Approval,Other,PAV-Petition Approval,2011-01-05T05:00:00Z,2011,1,2011-01-05T05:00:00Z,,2013-08-11T01:39:06Z,,0,0,0900006480bc55ae
FDA-2009-P-0595-0003,FDA,FDA-2009-P-0595,Interim Response to Public Citizen's Health Research Group,Other,LET-Letter,2010-06-08T04:00:00Z,2010,6,2010-06-08T04:00:00Z,,2010-10-29T01:10:26Z,,0,0,0900006480afe18d
FDA-2009-P-0595-0002,FDA,FDA-2009-P-0595,Acknowledgement Letter to Public Citizen Health Research Group,Other,ACK-Acknowledgement Letter,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,,2009-12-17T23:10:44Z,,0,0,0900006480a6b5a8
FDA-2009-P-0595-0001,FDA,FDA-2009-P-0595,Public Citizen Health Research Group - Citizen Petition,Other,CP-Citizen Petition,2009-12-17T05:00:00Z,2009,12,2009-12-17T05:00:00Z,,2011-01-05T16:57:05Z,,0,0,0900006480a6b5a7